Mounjaro is a new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Bruen R, Curley S, Kajani S, Crean D, O'Reilly ME, Lucitt MB, Godson CG, McGillicuddy FC, Belton O
Watkins P, Blainey J, Brewer D, Fitzgerald M, Malins J, OSullivan D, et al
Grau R, Punzn C, Fresno M, Iiguez MA (2006) Peroxisome-proliferator-activated receptor agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1
HY: Writing review & editing, Funding acquisition, Formal analysis, Data curation
References & Resources FDA Basaglar Prescribing Information FDA Ozempic Prescribing Information American Diabetes Association Standards of Care 2026 Disclaimer: This information is intended for general knowledge and informational purposes only and does not constitute medical advice
